DOLE
20.12.2022 17:17:38 CET | Business Wire | Press release
Dole plc (NYSE: DOLE) announced today the release of its first sustainability report since the 2021 merger of Total Produce plc and Dole Food Company. Building on its historical achievements, this report sets out the organization’s refreshed sustainability framework and offers a new set of environmental, social and governance (ESG) goals through 2030.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005564/en/
The Dole Way, Dole’s sustainability framework, focuses on robust governance and three core pillars—For Nature, For People and For Food—covering environmental, ethical and social and nutrition related issues. These three pillars incorporate key areas identified as being most material to the impact of our business’ operations.
- For Nature: By committing to the Science Based Target Initiative, Dole plc places climate action at the forefront of its priorities along with water stewardship, biodiversity, waste management and packaging reduction and innovation.
- For People: Directly employing 38,500 people globally while partnering with third party growers worldwide, Dole is committed to being an employer of choice, supporting local communities and protecting human rights across its supply chains.
- For Food: Dole is committing to promoting healthy nutrition and improving access to fresh produce through partnerships and donations.
“Dole has built market-leading positions across a wide range of fresh fruit and vegetable segments by incorporating sustainability into their growth models,” stated Rory Byrne, Dole plc Chief Executive Officer. “As our climate is changing, we are focused on identifying the related risks, adapting to the effects on our operations and minimizing our own impacts. We also recognize and relish the special role we can play in improving people’s lives and the contribution Dole can make to promoting good health and wellbeing.”
The report also lays the foundation for the promotion of regenerative farming practices across Dole’s own operations as well as on associated farms which will support the business’ ambitious climate goals.
Highlights of the report include Dole plc’s:
- First global carbon footprint collection including measuring and managing scope 1, scope 2 and scope 3 emissions resulting in a reduction of 4% in Scope 1 and 2 emissions (2021 over 2020)
- Investment in Renewal Energy with two 2.8 megawatt wind turbines in Dole Fresh Vegetables in Soledad, California and installed new solar panel system at Belfast, Ireland site with a capacity of 120 kWp
- Recognition by American-Costa Rican Chamber of Commerce (AmCham) of Dole affiliate, Standard Fruit Company de Costa Rica S.A., for their innovative project "De la Mano con Dole." The project positively impacts the social development of employees and their families using the Business Multidimensional Poverty Index (bMPI) methodology which measures poverty beyond only per capita income - to include access to health, education, housing, work, social protection and 16 other key indicators.
Xavier Roussel, Dole plc’s Chief Marketing and Sustainability officer, stated, “Although fresh produce has a low environmental footprint in comparison to other food sources, there is still much to do to further decrease our impacts and adapt to the effects of climate change. We are addressing those challenges for the long term with likeminded partners along the supply chain. Our vertically integrated business model allows us to research much in our own operations before expanding to our associated farmers which is instrumental to lead change in the industry.”
Adding, “Caring for our most important resources: our people, the nature around us and the food we deliver to the world is our way to contribute to society and will set us up for continued success.”
To view the full Dole plc 2022 Corporate Responsibility & Sustainability Report click here or visit www.doleplc.com.
About Dole plc
A global leader in fresh produce, Dole Plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place. For more information, please visit www.doleplc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005564/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
